SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/4584232D51C0B976D53BABEA822B148D0C0D90201132BBCDB155FE5E112E70733E2A51CABBFD883924CD2596032E28B7>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/4584232D51C0B976D53BABEA822B148D0C0D90201132BBCDB155FE5E112E70733E2A51CABBFD883924CD2596032E28B7
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/4584232D51C0B976D53BABEA822B148D0C0D90201132BBCDB155FE5E112E70733E2A51CABBFD883924CD2596032E28B7
http://www.w3.org/2000/01/rdf-schema#comment
"Studies suggest that inhibition of ELOVL6 could be a new therapeutic approach for the treatment of insulin resistance diabetes cardiovascular disease and other metabolic diseases."
xsd:string
http://purl.uniprot.org/uniprot/#_4EE467F2D8F09C525B1743A84D94D956B91086C60D9701DACF346D89631856D419F0E2FF56244649823D15184AF21020
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/4584232D51C0B976D53BABEA822B148D0C0D90201132BBCDB155FE5E112E70733E2A51CABBFD883924CD2596032E28B7
http://purl.uniprot.org/uniprot/Q9H5J4
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/4584232D51C0B976D53BABEA822B148D0C0D90201132BBCDB155FE5E112E70733E2A51CABBFD883924CD2596032E28B7
http://purl.uniprot.org/uniprot/#_Q9H5J4-mappedCitation-19259639
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/4584232D51C0B976D53BABEA822B148D0C0D90201132BBCDB155FE5E112E70733E2A51CABBFD883924CD2596032E28B7